J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 30.19 CNY 0.4%
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Jafron Biomedical Co Ltd

Revenue
2.6B CNY
Cost of Revenue
-550.4m CNY
Gross Profit
2.1B CNY
Operating Expenses
-1.1B CNY
Operating Income
1B CNY
Other Expenses
-196.3m CNY
Net Income
804.5m CNY

Income Statement
Jafron Biomedical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
509
N/A
532
+5%
547
+3%
537
-2%
544
+1%
566
+4%
612
+8%
662
+8%
719
+9%
777
+8%
846
+9%
925
+9%
1 017
+10%
1 105
+9%
1 219
+10%
1 290
+6%
1 432
+11%
1 516
+6%
1 643
+8%
1 776
+8%
1 951
+10%
2 151
+10%
2 269
+6%
2 417
+7%
2 675
+11%
2 794
+4%
3 041
+9%
2 919
-4%
2 491
-15%
2 367
-5%
1 949
-18%
1 952
+0%
1 922
-2%
2 094
+9%
2 406
+15%
2 632
+9%
Gross Profit
Cost of Revenue
(79)
(93)
(93)
(91)
(87)
(104)
(113)
(123)
(114)
(136)
(149)
(158)
(155)
(186)
(199)
(206)
(197)
(232)
(253)
(273)
(288)
(351)
(370)
(406)
(402)
(467)
(524)
(514)
(440)
(477)
(414)
(419)
(385)
(466)
(518)
(550)
Gross Profit
430
N/A
440
+2%
454
+3%
447
-2%
456
+2%
462
+1%
500
+8%
539
+8%
605
+12%
641
+6%
698
+9%
766
+10%
862
+12%
919
+7%
1 020
+11%
1 084
+6%
1 234
+14%
1 284
+4%
1 389
+8%
1 503
+8%
1 663
+11%
1 800
+8%
1 899
+5%
2 011
+6%
2 273
+13%
2 327
+2%
2 518
+8%
2 405
-4%
2 051
-15%
1 890
-8%
1 535
-19%
1 533
0%
1 537
+0%
1 629
+6%
1 888
+16%
2 082
+10%
Operating Income
Operating Expenses
(203)
(209)
(219)
(219)
(231)
(225)
(236)
(259)
(318)
(317)
(343)
(369)
(430)
(440)
(459)
(499)
(598)
(576)
(587)
(613)
(652)
(681)
(689)
(741)
(903)
(890)
(990)
(1 016)
(1 045)
(1 042)
(1 070)
(1 037)
(1 008)
(1 006)
(1 031)
(1 081)
Selling, General & Administrative
(182)
(206)
(214)
(214)
(202)
(224)
(240)
(243)
(285)
(299)
(324)
(358)
(398)
(423)
(447)
(481)
(550)
(541)
(556)
(587)
(604)
(639)
(635)
(666)
(755)
(750)
(840)
(843)
(851)
(862)
(855)
(826)
(794)
(800)
(826)
(882)
Research & Development
(17)
(4)
0
0
(22)
0
0
0
(27)
0
0
(21)
(45)
(40)
(56)
(62)
(67)
(67)
(70)
(69)
(78)
(89)
(101)
(129)
(164)
(194)
(222)
(240)
(234)
(267)
(269)
(268)
(212)
(246)
(244)
(244)
Depreciation & Amortization
(4)
(2)
0
0
(6)
0
0
0
(7)
0
0
0
(10)
0
0
0
(13)
0
0
0
(17)
0
0
0
(31)
0
0
0
(40)
0
0
0
(56)
0
0
0
Other Operating Expenses
(0)
3
(6)
(5)
(0)
(1)
3
(16)
(0)
(18)
(19)
10
23
23
45
43
32
33
39
43
47
48
46
53
47
53
72
68
81
87
53
57
54
39
39
44
Operating Income
227
N/A
231
+2%
235
+2%
228
-3%
226
-1%
237
+5%
263
+11%
281
+7%
287
+2%
324
+13%
355
+10%
397
+12%
432
+9%
480
+11%
562
+17%
585
+4%
636
+9%
708
+11%
802
+13%
890
+11%
1 011
+14%
1 119
+11%
1 210
+8%
1 270
+5%
1 370
+8%
1 437
+5%
1 528
+6%
1 389
-9%
1 006
-28%
848
-16%
466
-45%
495
+6%
529
+7%
623
+18%
857
+38%
1 001
+17%
Pre-Tax Income
Interest Income Expense
5
6
5
6
8
10
21
23
38
46
46
54
44
44
41
37
44
45
46
45
44
42
46
46
47
39
38
35
29
27
23
28
35
28
22
9
Non-Reccuring Items
0
0
0
0
(1)
0
(1)
0
18
0
0
0
(0)
0
0
0
(1)
0
0
0
(1)
0
0
1
(0)
1
1
1
(7)
(0)
0
0
(20)
3
3
3
Gain/Loss on Disposition of Assets
0
0
0
(0)
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
8
9
11
11
9
9
16
15
(2)
6
11
9
(3)
(5)
(19)
(18)
(8)
(18)
(20)
(19)
(22)
(11)
(12)
(15)
(9)
(11)
(11)
(11)
(11)
(20)
(20)
(23)
(22)
(24)
(29)
(36)
Pre-Tax Income
240
N/A
245
+2%
250
+2%
244
-2%
242
-1%
257
+6%
299
+17%
319
+6%
340
+7%
376
+11%
412
+9%
460
+12%
473
+3%
518
+10%
584
+13%
603
+3%
671
+11%
735
+9%
829
+13%
916
+11%
1 032
+13%
1 150
+11%
1 244
+8%
1 302
+5%
1 407
+8%
1 466
+4%
1 555
+6%
1 415
-9%
1 017
-28%
855
-16%
469
-45%
500
+7%
521
+4%
629
+21%
852
+35%
977
+15%
Net Income
Tax Provision
(39)
(35)
(41)
(40)
(39)
(42)
(49)
(52)
(56)
(61)
(66)
(73)
(72)
(78)
(88)
(91)
(103)
(112)
(126)
(138)
(159)
(178)
(191)
(193)
(211)
(218)
(232)
(212)
(136)
(114)
(59)
(67)
(95)
(115)
(151)
(183)
Income from Continuing Operations
200
210
209
204
202
215
251
266
285
315
345
387
401
440
496
512
569
623
703
778
873
972
1 053
1 109
1 196
1 247
1 323
1 203
881
742
410
432
426
514
701
794
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
1
1
2
2
2
3
3
3
2
2
2
1
1
1
2
4
9
9
9
7
11
10
10
10
Net Income (Common)
200
N/A
210
+5%
209
0%
204
-2%
202
-1%
215
+6%
251
+17%
266
+6%
284
+7%
315
+11%
345
+10%
387
+12%
402
+4%
442
+10%
498
+13%
514
+3%
571
+11%
626
+10%
706
+13%
780
+11%
875
+12%
974
+11%
1 055
+8%
1 111
+5%
1 197
+8%
1 249
+4%
1 325
+6%
1 207
-9%
890
-26%
751
-16%
419
-44%
440
+5%
436
-1%
525
+20%
711
+36%
804
+13%
EPS (Diluted)
0.29
N/A
0.3
+3%
0.3
N/A
0.26
-13%
0.27
+4%
0.27
N/A
0.33
+22%
0.35
+6%
0.36
+3%
0.39
+8%
0.43
+10%
0.48
+12%
0.51
+6%
0.56
+10%
0.63
+13%
0.65
+3%
0.73
+12%
0.78
+7%
0.88
+13%
0.97
+10%
1.1
+13%
1.21
+10%
1.35
+12%
1.39
+3%
1.49
+7%
1.52
+2%
1.64
+8%
1.49
-9%
1.12
-25%
0.93
-17%
0.51
-45%
0.53
+4%
0.55
+4%
0.64
+16%
0.87
+36%
0.98
+13%

See Also

Discover More